Rituximab chimeric anti-CD20 monoclonal antibody treatment for refractory hemolytic anemia in patients with lymphoproliferative disorders

Haematologica. 2003 Feb;88(2):223-5.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adult
  • Aged
  • Anemia, Hemolytic, Autoimmune / drug therapy*
  • Anemia, Hemolytic, Autoimmune / etiology
  • Antibodies, Monoclonal / administration & dosage*
  • Antibodies, Monoclonal / toxicity
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Female
  • Humans
  • Lymphoproliferative Disorders / complications*
  • Male
  • Middle Aged
  • Rituximab
  • Salvage Therapy
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Rituximab